BIOLIFE4D, which is developing synthetic human hearts by utilizing 3D bioprinting technology, filed on Friday with the SEC to raise up to $17 million in an initial public offering.
Because the company is offering units with warrants attached, BIOLIFE4D will be excluded from Renaissance Capital's 2022 IPO stats.
The company plans to create a patient-specific, fully functioning heart through 3D bioprinting using a patient’s own cells to eliminate the challenges of organ rejection and long donor waiting lists that exist in current organ transplant methods. As a precursor to a full-scale organ replacement product, BIOLIFE4D is focusing its initial efforts on producing a functional mini-heart that can be deployed for cardiotoxicity testing. Once optimized, the mini-heart will have four chambers, valves, greater vessels, musculature, electrical activity, and be capable of generating intraluminal pressures. Other opportunities for the company include manufacturing medical equipment such as cardiac valves, patches, and grafts.
The Buffalo Grove, IL-based company was founded in 2016 and plans to list on the Nasdaq under the symbol SAVU. Aegis Capital Corp. is the sole bookrunner on the deal. No pricing terms were disclosed.
